Berberine inhibits tumor necrosis factor‑α‑induced expression of inflammatory molecules and activation of nuclear factor‑κB via the activation of AMPK in vascular endothelial cells

Liu,Su‑Jian; Yin,Cai‑Xia; Ding,Ming‑Chao; Wang,Yi‑Zhong; Wang,Hong

doi:10.3892/mmr.2015.4061

Berberine inhibits tumor necrosis factor‑α‑induced expression of inflammatory molecules and activation of nuclear factor‑κB via the activation of AMPK in vascular endothelial cells

Authors:
- Su‑Jian Liu
- Cai‑Xia Yin
- Ming‑Chao Ding
- Yi‑Zhong Wang
- Hong Wang
View Affiliations

Affiliations: Department of Interventional Therapy of Peripheral Vascular, Aerospace Center Hospital, Beijing 100049, P.R. China, The Center of Anesthesia and Operation Room, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: July 8, 2015 https://doi.org/10.3892/mmr.2015.4061
Pages: 5580-5586

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Berberine, which is a well‑known drug used in traditional medicine, has been demonstrated to exert diverse pharmacological effects, including anti‑inflammatory effects. However, whether berberine can affect the production of inflammatory molecules in vascular endothelial cells remains to be elucidated. Therefore, the present study aimed to determine the effects of berberine, and the underlying molecular mechanisms of these effects. The effect of berberine on tumor necrosis factor (TNF)‑α‑induced inflammatory molecule expression was examined in cultured human aortic endothelial cells (HAECs). The HAECs were stimulated with TNF‑α and incubated with or without berberine. The activation of nuclear factor (NF)‑κB and adenosine monophosphate‑activated protein kinase (AMPK) were analyzed using western blotting, and the protein secretion of intercellular adhesion molecule (ICAM)‑1 and monocyte chemoattractant protein (MCP)‑1 was measured using ELISA kits. The mRNA expression levels of ICAM‑1 and MCP‑1 were analyzed using reverse transcription‑quantitative polymerase chain reaction. The results of the present study demonstrated that berberine significantly inhibited the TNF‑α‑induced expression of ICAM‑1 and MCP‑1, as well as the activation of NF‑κB in the HAECs. These effects were attenuated following co‑treatment with AMPK inhibitor compound C, or specific small interfering RNAs. In conclusion, the results of the present study indicated that berberine inhibits the TNF‑α‑induced expression of ICAM‑1 and MCP‑1, and the activation of NF‑κB in HAECs in vitro, possibly through the AMPK‑dependent pathway.

View Figures

View References

1	Chaabane C, Otsuka F, Virmani R and Bochaton-Piallat ML: Biological responses in stented arteries. Cardiovasc Res. 99:353–363. 2013. View Article : Google Scholar : PubMed/NCBI
2	Sprague AH and Khalil RA: Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 78:539–552. 2009. View Article : Google Scholar : PubMed/NCBI
3	Rabbani GH, Butler T, Knight J, Sanyal SC and Alam K: Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis. 155:979–984. 1987. View Article : Google Scholar : PubMed/NCBI
4	Saha P, Bhattacharjee S, Sarkar A, Manna A, Majumder S and Chatterjee M: Berberine chloride mediates its anti-leishmanial activity via differential regulation of the mitogen activated protein kinase pathway in macrophages. PLoS One. 6:e184672011. View Article : Google Scholar : PubMed/NCBI
5	Yu HH, Kim KJ, Cha JD, Kim HK, Lee YE, Choi NY and You YO: Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J Med Food. 8:454–461. 2005. View Article : Google Scholar : PubMed/NCBI
6	Choo BK and Roh SS: Berberine protects against esophageal mucosal damage in reflux esophagitis by suppressing proinflam-matory cytokines. Exp Ther Med. 6:663–670. 2013.PubMed/NCBI
7	Kuo CL, Chi CW and Liu TY: The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 203:127–137. 2004. View Article : Google Scholar : PubMed/NCBI
8	Mahata S, Bharti AC, Shukla S, Tyagi A, Husain SA and Das BC: Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol Cancer. 10:392011. View Article : Google Scholar : PubMed/NCBI
9	Katiyar SK, Meeran SM, Katiyar N and Akhtar S: p53 cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinog. 48:24–37. 2009. View Article : Google Scholar
10	Leng SH, Lu FE and Xu LJ: Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin. 25:496–502. 2004.PubMed/NCBI
11	Yin J, Hu R, Chen M, Tang J, Li F, Yang Y and Chen J: Effects of berberine on glucose metabolism in vitro. Metabolism. 51:1439–1443. 2002. View Article : Google Scholar : PubMed/NCBI
12	Hong Y, Hui SS, Chan BT and Hou J: Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. Life Sci. 72:2499–2507. 2003. View Article : Google Scholar : PubMed/NCBI
13	Zeng XH, Zeng XJ and Li YY: Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 92:173–176. 2003. View Article : Google Scholar : PubMed/NCBI
14	Liang KW, Ting CT, Yin SC, Chen YT, Lin SJ, Liao JK and Hsu SL: Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol. 71:806–817. 2006. View Article : Google Scholar : PubMed/NCBI
15	Lee S, Lim HJ, Park HY, Lee KS, Park JH and Jang Y: Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model. Atherosclerosis. 186:29–37. 2006. View Article : Google Scholar
16	Meng S, Wang LS, Huang ZQ, Zhou Q, Sun YG, Cao JT, Li YG and Wang CQ: Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp Pharmacol Physiol. 39:406–411. 2012. View Article : Google Scholar : PubMed/NCBI
17	Carbone F and Montecucco F: Inflammation in arterial diseases. IUBMB Life. 67:18–28. 2015. View Article : Google Scholar : PubMed/NCBI
18	Korcum AF, Sanlioglu S, Aksu G, Tuncel N and Erin N: Radiotherapy-induced decreases in substance P levels may potentiate melanoma growth. Mol Med Rep. 2:319–326. 2009.PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
20	Liu SJ, Yin CX, Ding MC, Xia SY, Shen QM and Wu JD: Berberine suppresses in vitro migration of human aortic smooth muscle cells through the inhibitions of MMP-2/9, u-PA, AP-1, and NF-κB. BMB Rep. 47:388–392. 2014. View Article : Google Scholar :
21	Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC and Ho TY: Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol Res. 56:193–201. 2007. View Article : Google Scholar : PubMed/NCBI
22	Choi BH, Ahn IS, Kim YH, Park JW, Lee SY, Hyun CK and Do MS: Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol Med. 38:599–605. 2006. View Article : Google Scholar
23	Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS and Kim JB: Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 296:E955–E964. 2009. View Article : Google Scholar : PubMed/NCBI
24	Charo IF and Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res. 95:858–866. 2004. View Article : Google Scholar : PubMed/NCBI
25	Kaneko H, Anzai T, Morisawa M, Kohno T, Nagai T, Anzai A, Takahashi T, Shimoda M, Sasaki A, Maekawa Y, et al: Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis. 217:350–357. 2011. View Article : Google Scholar : PubMed/NCBI
26	Melgarejo E, Medina MA, Sánchez-Jiménez F and Urdiales JL: Monocyte chemoattractant protein-1: A key mediator in inflammatory processes. Int J Biochem Cell Biol. 41:998–1001. 2009. View Article : Google Scholar
27	Egashira K: Molecular mechanisms mediating inflammation in vascular disease: Special reference to monocyte chemoattractant protein-1. Hypertension. 41:834–841. 2003. View Article : Google Scholar : PubMed/NCBI
28	De Martin R, Hoeth M, Hofer-Warbinek R and Schmid JA: The transcription factor NF-kappaB and the regulation of vascular cell function. Aterioscler Thromb Vasc Biol. 20:E83–E88. 2000. View Article : Google Scholar
29	Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
30	Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, Dole W and Rutledge JC: Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics. 11:21–30. 2002. View Article : Google Scholar : PubMed/NCBI
31	Brasier AR: The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res. 86:211–218. 2010. View Article : Google Scholar : PubMed/NCBI
32	Aljada A, Ghanim H, Saadeh R and Dandona P: Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab. 86:450–453. 2001.PubMed/NCBI
33	Towler MC and Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 100:328–341. 2007. View Article : Google Scholar : PubMed/NCBI
34	Fisslthaler B and Fleming I: Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res. 105:114–127. 2009. View Article : Google Scholar : PubMed/NCBI
35	Cacicedo JM, Yagihashi N, Keaney JF Jr, Ruderman NB and Ido Y: AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun. 324:1204–1209. 2004. View Article : Google Scholar : PubMed/NCBI
36	Okayasu T, Tomizawa A, Suzuki K, Manaka K and Hattori Y: PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci. 82:884–891. 2008. View Article : Google Scholar : PubMed/NCBI
37	Hattori Y, Nakano Y, Hattori S, Tomizawa A, Inukai K and Kasai K: High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappaB activation in vascular endothelial cells. FEBS Lett. 582:1719–1724. 2008. View Article : Google Scholar : PubMed/NCBI
38	Hattori Y, Suzuki K, Hattori S and Kasai K: Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 47:1183–1188. 2006. View Article : Google Scholar : PubMed/NCBI